Pfizer (NYSE:PFE) Stock Gets Price Target Increase from Freedom Broker

Pfizer (NYSE:PFE) had its price objective raised by Freedom Broker from $33.00 to $34.00 in a report released on Friday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Freedom Broker‘s target price indicates a potential upside of 15.72% from the company’s current price.

A number of other analysts have also weighed in on the stock. Cantor Fitzgerald upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Thursday, October 8th. FBN Securities set a $34.00 price target on shares of Pfizer in a research note on Friday. HSBC boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “hold” rating in a report on Thursday, September 10th. Guggenheim increased their price objective on shares of Pfizer from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Bank of America reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Six analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $30.39.

Pfizer Stock Down 1.7%

PFE traded down $0.50 on Friday, hitting $29.38. 48,291,518 shares of the company were exchanged, compared to its average volume of 39,936,480. Pfizer has a twelve month low of $23.62 and a twelve month high of $31.44. The company has a market cap of $167.46 billion, a price-to-earnings ratio of 41.97, a price-to-earnings-growth ratio of 2.04 and a beta of 0.31. The company has a current ratio of 1.42, a quick ratio of 0.96 and a debt-to-equity ratio of 0.67. The firm has a 50-day moving average price of $28.74 and a two-hundred day moving average price of $26.90.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. The company had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. Pfizer’s revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter last year, the company earned $0.87 EPS. On average, equities analysts predict that Pfizer will post 3.02 earnings per share for the current year.

Institutional Trading of Pfizer

Institutional investors have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC increased its position in shares of Pfizer by 11.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,132,291 shares of the biopharmaceutical company’s stock worth $31,840,000 after purchasing an additional 112,523 shares in the last quarter. Pictet Asset Management Holding SA boosted its position in shares of Pfizer by 62.8% in the 3rd quarter. Pictet Asset Management Holding SA now owns 4,721,719 shares of the biopharmaceutical company’s stock valued at $134,667,000 after purchasing an additional 1,820,944 shares during the period. Leelyn Smith LLC boosted its position in shares of Pfizer by 3.9% in the 3rd quarter. Leelyn Smith LLC now owns 128,235 shares of the biopharmaceutical company’s stock valued at $3,657,000 after purchasing an additional 4,851 shares during the period. Verus Capital Partners LLC grew its stake in Pfizer by 5.1% during the 3rd quarter. Verus Capital Partners LLC now owns 16,716 shares of the biopharmaceutical company’s stock worth $477,000 after buying an additional 805 shares during the last quarter. Finally, W.G. Shaheen & Associates DBA Whitney & Co purchased a new position in Pfizer during the 3rd quarter worth approximately $221,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
• Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
• Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
• Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips

About Pfizer